glp 1 drugs for weight loss covered by insurance The GLP-1 Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Does health insurance cover GLP-1

doi: 10.1038/ijo.2013.149 91 le RouxCWAstrupAFujiokaKGreenwayFLauDCWVan GaalLet al

Apart from these cardiovascular mechanisms, increased BMI independently correlates with mortality risk

Figure S17

Lancet 14:110 Son JW, Kim S (2020) Comprehensive review of current and upcoming anti-obesity drugs

In the second trial, SURPASS-2, tirzepatide administered at doses of 5 mg, 10 mg, or 15 mg showed superior efficacy compared to semaglutide (1 mg) in reducing body weight and HbA1c levels over 40 weeks in patients with T2DM inadequately controlled with metformin [66]

Recent final draft guidance from NICE (2026a) has recommended semaglutide up to a dose of 2.4 mg subcutaneously once weekly for people without diabetes and: with pre-existing CVD (previous MI, stroke or peripheral vascular disease) and a BMI of 27 kg/m 2 for CV protection (to reduce CV death, non-fatal MI, non-fatal stroke)